Please
note that 02xl.com provides this information for the benefit of the disease
community. 02xl.com is not a medical provider or health care facility and thus
can neither diagnose any disease or disorder nor endorse or recommend any
specific medical treatments. Patients must rely on the personal and
individualized medical advice of their qualified health care professionals
before seeking any information related to their particular diagnosis, cure or
treatment of a condition or disorder.
Almourani R, Chinnakotla B, Patel R, et al. Diabetes and cardiovascular disease: an update. Curr Diab Rep. 2019;19:161.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709–33.
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37:2864–83.
Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
González-Pérez A, Saez M, Vizcaya D, et al. Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK. BMJ Open Diabetes Res Care. 2021;9:e002146.
American Diabetes Association professional practice committee. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S17–38.
National Institute for Health and Care Excellence (NICE). 2019 surveillance of diabetes (NICE guidelines NG17, NG18, NG19 and NG28). London, 2019
Gerstein HC, Colhoun HM, Dagenais GR, REWIND Investigators, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30.
Marso SP, Daniels GH, Brown-Frandsen K, LEADER Trial Investigators, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
Marso SP, Bain SC, Consoli A, SUSTAIN-6 Investigators, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.
Gerstein HC, Colhoun HM, Dagenais GR, REWIND Investigators, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131–8.
Mann JFE, Ørsted DD, Brown-Frandsen K, LEADER Steering Committee Investigators, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839–48.
Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:859–69.
Lopez PD, Bhatia K, Bohra C, et al. Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure. Am J Cardiol. 2022;181:87–93.
Sawami K, Tanaka A, Node K. Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2022;21:176.
Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319:1580–91.
Huixing L, Di F, Daoquan P. Effect of glucagon-like peptide-1 receptor agonists on prognosis of heart failure and cardiac function: a systematic review and meta-analysis of randomized controlled trials. Clin Ther. 2023. https://doi.org/10.1016/j.clinthera.2022.12.006.
Chan YH, Chao TF, Chen SW, et al. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovasc Diabetol. 2022;21:118.
Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;138:2908–18.
Bloomgarden Z. The kidney and cardiovascular outcome trials. J Diabetes. 2018;10:88–9.
Shao SC, Chan YY, Kao Yang YH, et al. The chang gung research database-a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019;28:593–600.
McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32:3388–414.
Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149–58.
Pratley RE, Nauck M, Bailey T, 1860-LIRA-DPP-4 Study Group, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–56.
Bailey TS, Takács R, Tinahones FJ, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab. 2016;18:1191–8.
Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189.
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62.
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
Mazumder MK, Paul R, Bhattacharya P, et al. Neurological sequel of chronic kidney disease: from diminished acetylcholinesterase activity to mitochondrial dysfunctions, oxidative stress and inflammation in mice brain. Sci Rep. 2019;9:3097.
Ghoshal S, Freedman BI. Mechanisms of stroke in patients with chronic kidney disease. Am J Nephrol. 2019;50:229–39.
Cai X, She M, Xu M, et al. GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction. Int J Biol Sci. 2018;14:1696–708.
Tanaka T, Higashijima Y, Wada T, et al. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014;86:701–11.
Górriz JL, Soler MJ, Navarro-González JF, et al. GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med. 2020;9:947.
Jardine MJ, Hata J, Woodward M, et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis. 2012;60:770–8.
Hviid AVR, Sørensen CM. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. Am J Physiol Renal Physiol. 2020;318:F443–54.
Chen JJ, Wu CY, Jenq CC, et al. Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. JAMA Netw Open. 2022;5:e221169.
Pfeffer MA, Claggett B, Diaz R, ELIXA Investigators, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.
Husain M, Birkenfeld AL, Donsmark M, PIONEER 6 Investigators, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51.
Holman RR, Bethel MA, Mentz RJ, EXSCEL Study Group, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.
Hernandez AF, Green JB, Janmohamed S, Harmony Outcomes committees and investigators, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29.
Pasternak B, Wintzell V, Eliasson B, et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care. 2020;43:1326–35.
Steven S, Hausding M, Kröller-Schön S, et al. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol. 2015;110:6.
Yang F, Zeng F, Luo X, et al. GLP-1 receptor: a new target for sepsis. Front Pharmacol. 2021;12: 706908.
Choi JH, Kim SJ, Kwon SK, et al. Renal tubular glucagon-like peptide-1 receptor expression is increased in early sepsis but reduced in chronic kidney disease and sepsis-induced kidney injury. Int J Mol Sci. 2019;20:6024.
Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219–24.
Share your experience. Everybody’s experience of Overweight & Obesity is different. There are many ways to address people’s lived experience of Overweight & Obesity, that must work for the individual. Sharing your story can help change perspectives and inspire others who may feel alone and unrepresented. You can also hear from other people about their experience of Overweight & Obesity.
Thanks for being there: We need your help. The 02xl Overweigt & Obesity
Community continues to grow but revenues have never been harder to maintain.
With the rise of Ad Blockers, and Facebook - our traditional revenue sources via
quality network advertising continues to decline. And unlike so many other news
sites, we don't have a paywall - with those annoying usernames and passwords.
Our news coverage takes time and effort to publish 365 days a year. If you find
our news sites informative and useful then please consider becoming a regular
supporter or for now make a one off contribution.
Source link
